Skip to main content

Table 3 Timetrends, all patients distributed in the five equal time periods (5 y each) and compared to available MCR data

From: Treatment strategies for oesophageal cancer - time-trends and long term outcome data from a large tertiary referral centre

Time period

 

I: 1983-1987

II: 1988-1992

III: 1993-1997

IV: 1998-2002

V: 2003-2007

  

n = 143(%)

n = 98(%)

n = 69(%)

n = 108(%)

n = 85(%)

Gender

M

115(80.4)

76(77.6)

52(75.4)

92(85.2)

65(76.5)

 

MCR

(84.0)

(83.2)

(83.0)

(79.0)

(80.4)

Age

median y

59

60

59

60

65

 

MCR

58

59

61

65

66

Histology

AC/SCC

23(16.1)/117(81.8)

14(14.3)/81(82.7)

12(17.4)/56(81.2)

23(21.3)/81(75)

23(27.1)/60(70.6)

 

MCR

(16.5)/(83.5)

(22.9)/(77.1)

(27.6)/(72.4)

  

Grading

G3+4

61(42.7)

48(49)

40(58)

64(59.3)

49(57.6)

T

T3+4

76(53.2)

61(62.2)

55(79.7)

90(83.4)

65(76.6)

N1

 

53(37.1)

36(36.7)

40(58)

65(60.2)

59(69.4)

M1

 

27(20.9)

17(19.1)

15(22.1)

29(27.6)

25(29.8)

UICC

I-IIB

68(47.6)

45(45.9)

24(34.8)

32(29.6)

21(24.7)

 

MCR

(34.4)

(37.0) 1988-2007

   
 

III-IV

61(42.7)

43(43.9)

43(62.3)

74(68.5)

63(74.1)

 

MCR

(51.1)

(63.1) 1988-2007

   
 

unknown

14(9.8)

10(10.2)

2(2.9)

2(1.9)

1(1.2)

Therapy

definitive

94(65.7)

66(67.3)

49(71)

77(71.3)

67(78.8)

 

RT/RCT

55(58.5)/38(40.4)

37(56.1)/29(43.9)

13(26.5)/36(73.5)

10(13)/67(87)

11(16.4)/56(83.6)

 

adjuvant

21(14.7)

4(4.1)

9(13.0)

10(9.3)

7(8.2)

 

RT/RCT

14(66.7)/4(19)

1(25)/3(75)

3(33.3)/6(66.7)

2(20)/8(80)

0/7(100)

 

neoadjuvant

20(14.0)

24(24.5)

10(14.5)

19(17.6)

10(11.8)

 

RT/RCT

7(35)/12(60)

4(16.7)/19(79.2)

2(20)/8(80)

3(15.8)/16(84.2)

1(10)/8(80)

RT, M0-patients

 

56(56.6)

26(36.1)

13(24.5)

9(11.8)

6(10.3)

RCT, M0-patients

 

43(43.4)

46(63.9)

40(75.5)

67(88.2)

52(89.7)

Surgery, M0-patients

 

33(32.7)

22(30.6)

16(30.2)

25(33.8)

16(27.1)

RT dose in Gy, M0-pat.

≤54

45(47.4)

36(50)

23(43.4)

38(51.4)

20(33.9)

 

> 54 - < 60

4(4.2)

0

6(11.3)

17(23)

27(45.8)

 

60+

46(48.4)

36(50)

24(45.3)

19(25.7)

12(20.3)

2D/3D-planning

 

142(99.3)/0

98(100)/0

65(94.2)/1(1.4)

7(6.5)/99(91.7)

2(2.4)/82(96.5)

Peri-therapy death

19(13.3)

11(11.2)

9(13.0)

15(13.9)

8(9.5)

Therapy break up due to complications

13(9.1)

4(4.1)

7(10.1)

13(12.0)

6(7.1)

Overall survival all/M0

median

18.9/20.7

20.6/26.1

22.6/27.3

20.7/24.3

20.3/29.7

 

1 y

(41.1)/(43.7)

(40.2)/(52.2)

(44.9)/(54.7)

(40.7)/(44.7)

(48.8)/(58.7)

 

3 y

(7.1)/(8.7)

(15.1)/(18.3)

(14.5)/(18.9)

(17.6)/(19.7)

(15.9)/(19.4)

 

5 y

(4.0)/(5.5)

(8.6)/(8.2)

(10.1)/(13.2)

(9.3)/(11.8)

(9.8)/(15.1)